Advertisement
China Biologic's common stock began trading on the NASDAQ Global Market onDecember 2, 2009, under the ticker symbol "CBPO."
"We are honored to ring the NASDAQ opening bell to celebrate our listingon one of the most prestigious equity markets in the world," said Mr. ChaoMing Zhao, China Biologic's Chief Executive Officer. "We would like to thankour shareholders, dedicated employees, board of directors, management team,and all other parties who have contributed to our success to date."
Advertisement
A live webcast of the NASDAQ Opening Bell (starting from 9:20 a.m. ET)will be available at: http://www.nasdaq.com/about/marketsitetowervideo.asx
About China Biologic Products, Inc.
China Biologic Products, Inc. (the "Company"), through its indirectmajority-owned subsidiaries, Shandong Taibang Biological Products Co. Ltd. andGuiyang Dalin Biologic Technologies Co., Ltd, and its equity investment inXi'an Huitian Blood Products Co., Ltd., is currently the largestnon-state-owned plasma-based biopharmaceutical company in China. The Companyis a fully integrated biologic products company with plasma collection,production and manufacturing, research and development, and commercialoperations. The Company's plasma-based biopharmaceutical products areirreplaceable during medical emergencies, and are used for the prevention andtreatment of various diseases. The Company sells its products to hospitals andother healthcare facilities in China. For more information please visit theCompany's website http://www.chinabiologic.com .
Safe Harbor Statement
This release may contain certain "forward-looking statements" relating tothe business of China Biologic Products, Inc. and its subsidiary companies.All statements, other than statements of historical fact included herein are"forward-looking statements," including statements regarding: the significanceof the Company's listing on the NASDAQ Global Market; the ability of theCompany to achieve its commercial objectives; the business strategy, plans andobjectives of the Company and its subsidiaries; and any other statements ofnon-historical information. These forward-looking statements are oftenidentified by the use of forward-looking terminology such as "believes,""expects" or similar expressions, and involve known and unknown risks anduncertainties. Although the Company believes that the expectations reflectedin these forward-looking statements are reasonable, they do involveassumptions, risks and uncertainties, and these expectations may prove to beincorrect. Investors should not place undue reliance on these forward-lookingstatements, which speak only as of the date of this press release. TheCompany's actual results could differ materially from those anticipated inthese forward-looking statements as a result of a variety of factors,including those discussed in the Company's periodic reports that are filedwith the Securities and Exchange Commission and available on its website(http://www.sec.gov ). All forward-looking statements attributable to theCompany or persons acting on its behalf are expressly qualified in theirentirety by these factors. Other than as required under the securities laws,the Company does not assume a duty to update these forward-looking statements.For more information, please contact: Company Contact: Mr. Y. Tristan Kuo Chief Financial Officer China Biologic Products, Inc. Tel: +86-538-6202206 Email: [email protected] Web: http://www.chinabiologic.com Investor Relations Contact: CCG Investor Relations Mr. Athan Dounis, Account Manager Tel: +1-646-213-1916 Email: [email protected] Mr. Crocker Coulson, President Tel: +1-646-213-1915 Email: [email protected] Web: http://www.ccgirasia.com
SOURCE China Biologic Products, Inc.
